Evonik's 40% Earnings Jump Misses the Mark as Jefferies Keeps Faith

Evonik delivered a sharp improvement in underlying profit last quarter, yet the headline number still fell just shy of what the market had pencilled in — a nuance that sits at the heart of Jefferies' decision to reaffirm its buy rating on the specialty chemicals maker.

The broker kept its price target unchanged at €20, which now rests below the current share price of €20.86. That combination sends a mixed message to investors: the recommendation is constructive, but the target leaves no headroom from today's level. Analyst Helena Xu pointed to adjusted operating profit as the sticking point, noting it came in marginally under the consensus estimate.

Growth versus expectations

Adjusted EBITDA for the third quarter of 2026 climbed 40% year on year to €629 million. The Vara Research consensus, as reported by Reuters, had forecast €633.2 million. The gap is small, but it separates two distinct stories — solid expansion against the prior year, and a slight shortfall against what analysts had anticipated.

That tension explains the uneven early trading reaction. According to media reports, the stock softened after the figures landed before turning positive later in the session, as a more upbeat full-year outlook offset the narrowly missed earnings mark.

The bottom line tells a similarly layered story. Evonik's net loss narrowed to €53 million from €106 million a year earlier, while revenue advanced 13% to €3.83 billion. The company also booked €313 million in provisions for additional ETM measures.

Why the operating gain isn't the whole picture

Higher selling prices and increased volumes drove the improvement, meaning the result does not rest on pricing alone. A weaker competitive backdrop added a further tailwind: Reuters reported supply disruptions among Asian rivals stemming from the Middle East crisis, a factor that flattered Evonik's position without representing a durable lift in demand.

Investors weighing the recovery therefore need to keep two measures apart. The adjusted figure shows clear momentum, but the group result confirms Evonik has yet to return to profitability. Reading the EBITDA alone would obscure that distinction.

The outlook carries the bullish case

Management expects adjusted EBITDA for the full of 2026 in the upper half of its €2.0 billion to €2.2 billion range, and anticipates fourth-quarter earnings above the prior-year level. Confidence, in other words, extends beyond the quarter just closed — though it remains a forecast rather than a delivered result.

Against that backdrop, the Jefferies call cannot be read as extra upside on paper. The operating rebound and brighter company guidance argue for an improved business picture; the target sitting under the market price puts a firm ceiling on how far the bullish broker note can carry the stock.